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1. Introduction 
Kawasaki disease (KD) is an acute febrile systemic vasculitis that was first described by 
Kawasaki et al.(1) in 1967 in Japanese(2) and in 1974 in English. Currently, it is the leading 
cause of acquired heart disease in children in developed countries; however, its etiology 
remains unknown.(3-5) KD mainly affects children less than 5 years of age, especially those 
in Asian countries. In Japan, Korea, and Taiwan, the incidence ranges from 69 to 218 cases 
per 100,000 children less than 5 years of age.(6-9) The incidence of KD in Taiwan has in-
creased from 66 to 69 cases per 100,000 children aged less than 5 years.(9-12) Its incidence 
worldwide is increasing, especially in Japan, where, in 2010, Nakamura et al. reported the 
country’s highest rate of 239.6 cases per 100,000 children aged 0–4 years.(13) An epidemio-
logic survey of KD in Taiwan spanning 2003–2006 found that 1.5% of all cases was recurrent 
(having a second episode of KD and receiving intravenous immunoglobulin [IVIG] treat-
ment).(9) In Taiwan, KD occurs most frequently in the summer (April to June) and least 
frequently in the winter; for unknown reasons, its seasonal occurrence varies in other coun-
tries. The most serious complication of KD is the development of coronary artery lesions 
(CAL), including myocardial infarction, coronary artery fistula formation,(14) coronary 
artery dilatation, and coronary artery aneurysm.(15)  
The most commonly used definition of CAL (also known as coronary artery abnormality 
[CAA] or CAL) is based on the Japanese Ministry of Health criteria: maximum absolute 
internal diameter > 3 mm in children younger than 5 years of age or >4 mm in children 5 
years and older, or a segmental diameter 1.5 times greater than that of an adjacent segment, 
or the presence of luminal irregularity.(16-21) Coronary arteries should be corrected relative 
to body surface area (if available) and expressed as standard deviation units from the mean 
(Z scores).(22) Several studies analyzed CAL, including aortic root dimension,(23) and 
transient CAL (the definition of “transient” varies among studies, from 30 days to 6–8 weeks 
Current Basic and Pathological Approaches to  
the Function of Muscle Cells and Tissues – From Molecules to Humans 
 
208 
after diagnosis of disease). Thus, KD patients with coronary artery ectasia or dilatation that 
disappears within the first 8 weeks after disease onset are defined as having transient ectasia 
or dilatation (transient CAL). Kuo et al. reported the serious CAL analysis that comprised 
341 KD patients;(24) 35% of KD patients had dilatation during the acute phase of admission, 
17.2% still had dilatation 1 month after disease onset, 10.2% had dilatation at 2 months 
follow-up, and 4.1% had persistent CAL for more than 1 year.(25, 26) Ectasia or transient 
dilatations are somewhat considered to be a risk for a subsequent cardiovascular event or 
inflammation duration, rather than normal status.(27)  
Although the clinical features of KD are recognizable, its underlying immunopathogenetic 
mechanisms are still under investigation, particularly the agent responsible for the devel-
opment of CAL. KD is regarded as an autoimmune disorder rather than an infectious dis-
ease.(23) Kuo et al. reported that persistent monocytosis after IVIG treatment is associated 
with CAL formation.(28) Eosinophils in KD patients were also higher than that in age-
matched febrile controls. In addition, IVIG treatment significantly increased eosinophils in 
KD patients. This increase of eosinophils after IVIG treatment is inversely correlated with 
IVIG treatment failure in KD.(29) Further studies have shown that eosinophil changes after 
IVIG treatment were positively correlated with changes in interleukin (IL)-5 levels. An in-
crease in eosinophils and IL-5 levels after IVIG treatment is inversely correlated with CAL 
formation.(30) Recently, we found that incidence of allergic diseases (asthma and allergic 
rhinitis) after onset of KD were higher than that in age and sex-matched controls in a popu-
lation cohort in Taiwan. 
2. Allergy potential of Kawasaki disease patients 
Brosius et al.(31) showed that the incidence of atopic dermatitis among children with KD 
was 9 times greater than that of controls. Burns et al.(32) reported associations of KD with 
atopic dermatitis and allergy, elevated serum IgE levels, and eosinophilia and that increased 
circulating numbers of monocytes/macrophages expressing the low-affinity IgE receptor 
(FCεR2) may be related to the effects of IL-4. Liew et al.(33) reported that KD may be a risk 
factor for subsequent allergic disease and postulated that KD occurs more frequently in 
children at risk of immune disequilibrium, with an initial abnormal inflammatory response, 
and subsequently, more allergic manifestations. Currently, Webster et al.(34) also reported 
that KD patients were more likely to have been admitted at least once with asthma/allergy 
than controls were. From our previous reports, we found that the T-helper (Th) type 2 im-
mune response was elevated in the acute stage of KD, including eosinophils,(29) IL-4, IL-
5,(35) and eotaxin. The eosinophil changes were correlated to changes of IL-5 levels but not 
to eosinophil cationic protein (ECP) levels, suggesting a Th2 immune reaction in KD. There 
are several lines of evidence pointing to an abnormal Th1/Th2 balance in KD patients.(28, 29, 
35-39) Lin et al.(40) reported the comparison of eosinophils in KD and enterovirus (EV) pa-
tients with IVIG treatment and demonstrated a more significant eosinophil increase in KD 
patients. EV patients also had elevated eosinophil levels after IVIG therapy, but not as high 
as that of the KD patients after IVIG treatment. This may indicate an imbalance of the 
Th1/Th2 immune response, with a skewed Th2 response in KD. 
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3. Clinical phenotype and presentation of Kawasaki disease 
As shown in Figures 1–8, the clinical characteristics of KD patients include fever lasting 
longer than 5 days, diffuse mucosal inflammation, bilateral non-purulent conjunctivitis, 
dysmorphic skin rashes, indurative angioedema over the hands and feet, and cervical 
lymphadenopathy. In addition to the diagnostic criteria, there is a broad range of non-
specific clinical features, including irritability, uveitis, aseptic meningitis, cough, vomiting, 
diarrhea, abdominal pain, gallbladder hydrops, urethritis, arthralgia, arthritis, 
hypoalbuminemia,(5) liver function impairment, and heart failure.(4, 29, 41) 
 
Figure 1. Dysmorphic skin rash of Kawasaki disease 
 
Figure 2. Skin rash and neck lymphadenopathy (right side, >1.5 cm in diameter) 
Current Basic and Pathological Approaches to  
the Function of Muscle Cells and Tissues – From Molecules to Humans 
 
210 
 
Figure 3. Strawberry tongue  
 
Figure 4. Face of Kawasaki disease patient exhibiting conjunctivitis, fissured lips, and skin rashes 
 
Figure 5. BCG injection site indurations 
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Figure 6. Fissured lips and swelling of finger joints 
 
 
Figure 7. Induration change over foot 
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Figure 8. Induration change over palm 
3.1. Diagnosis of Kawasaki disease 
To date, there is no specific diagnostic laboratory test for KD. Diagnosis is based on the 
clinical phenotype, i.e., presence of fever lasting longer than 5 days and fulfillment of 4 of 5 
specific clinical criteria. In Japan, at least 5 of 6 criteria (fever and 5 other clinical criteria) 
should be fulfilled for a diagnosis of KD. However, patients with 4 of the principal clinical 
features can be diagnosed when coronary aneurysm or dilatation is identified.(42) From the 
Japanese Circulation Society Joint Working Groups criteria (JCS 2008, Guidelines for Diag-
nosis and Management of Cardiovascular Sequelae in Kawasaki Disease),(43) KD can be 
diagnosed even when fever lasts less than 5 days. However, according to the American 
Heart Association (AHA) criteria,(15) fever lasting more than 5 days is essential for the di-
agnosis of KD. 
Some patients who do not fulfill the criteria have been diagnosed with “incomplete” or 
“atypical” KD, a diagnosis often based on echocardiographic identification of CAL. The 
term “incomplete” may be preferable to “atypical” because these patients have insufficient 
criteria instead of atypical presentation.(15)  
In countries with a bacillus Calmette-Guérin (BCG) vaccine policy (i.e., Taiwan and Japan), 
KD with erythematous induration or even ulceration of the BCG scar has been observed in 
one-third to half of KD patients (the incidence of BCG site induration is higher than that of 
neck lymphadenopathy in these countries).(3) Uehara et al.(44) reported that redness or the 
formation of a crust at the BCG inoculation site is a useful diagnostic sign for KD in children 
aged 3–20 months. Even if patients exhibit 4 or fewer signs of the clinical criteria for KD, 
physicians should consider the redness or crust formation at the BCG inoculation site as a 
possible indicator of KD.  
Incomplete cases of KD are not uncommon (up to 15–20%). The incidence of CAL in patients 
exhibiting 4 principal symptoms of KD is slightly higher than that in patients with 5 to 6 
principal symptoms.(45) Presentation of a small number (<4) of principal symptoms does 
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not indicate a milder form of the disease. Patients with at least 4 principal symptoms require 
the same treatment as patients with complete (typical) presentation of KD, and those with 3 
or fewer principal symptoms should be treated similarly when they meet the supplementary 
criteria. Herein, common supplementary criteria for the diagnosis of incomplete KD are 
introduced. 
  
Figure 9. Flowchart of Kawasaki disease management 
Incomplete KD is more common in young infants than in older children, making accurate 
diagnosis and timely treatment especially important in these young patients, who are at 
substantial risk of developing coronary abnormalities.(46, 47) The incidence of KD is 
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actually higher than that previously reported worldwide, partly because earlier reports did 
not take incomplete forms into account. The AHA criteria (2004), which incorporate 
suggestions for laboratory tests and early echocardiography, are helpful for diagnosing 
incomplete KD.(41, 48) Consultation with an expert (cardiologist, immunologist, or 
rheumatologist) should be sought whenever assistance in making a diagnosis is needed. 
Patients with fever for 5 days or more (with 2 or 3 principal clinical features for KD) without 
other causes should undergo laboratory testing, and if there is evidence of systemic 
inflammation, an echocardiogram should be obtained even if the patient does not fully meet 
the clinical criteria for KD. Likewise, infants 6 months or younger with fever for 7 days or 
more without other causes should undergo laboratory testing, and if evidence of systemic 
inflammation is found, an echocardiogram should be obtained even if the infant fulfills no 
clinical criteria for KD.(15) 
The 2004 AHA supplemental laboratory criteria include (1) albumin ≤ 3.0 g/dL; (2) anemia 
for age; (3) elevation of alanine aminotransferase (ALT); (4) platelets after 7 days ≥ 
450,000/mm3; (5) white blood cell count ≥ 15,000/mm3; and (6) urine ≥ 10 white blood 
cells/high-power field.(15) If a patient has more than 3 supplementary criteria, incomplete 
KD is diagnosed and IVIG should be prescribed before performing echocardiography.(15) 
The flowchart for incomplete KD diagnosis and treatment are depicted in Figure 9. 
4. Treatment for Kawasaki disease 
The standard treatment for KD is IVIG (2 g/kg) infusion for 8–12 hours with high-dose 
aspirin (80–100 mg/[kg·day]).(20, 24, 29) The most serious complication of KD is the 
development of CAL, including myocardial infarction, coronary artery dilatation, coronary 
artery aneurysms, and coronary fistula formation.(25, 30, 49) Coronary artery aneurysms 
occur as a sequela of the vasculitis in 20–25% of untreated children. There are several risk 
factors for developing coronary arteritis, such as low serum albumin, age younger than 1 
year, and long duration of the fever before treatment. Young patients with low albumin run 
a very high risk for CAL and IVIG treatment resistance.(5, 29) Although the introduction of 
IVIG therapy has greatly decreased the rate of coronary aneurysm to 3–10% of patients still 
develop some type of CAL. Durongpisitkul et al. showed that 11.6% patients are 
unresponsive to initial IVIG (2 g/kg) treatment. The worst prognosis occurs in children with 
so-called “giant aneurysms of the coronary arteries” (those with a maximal diameter of >8 
mm), as thrombosis is promoted both by sluggish blood flow within the massively dilated 
vascular space and by the frequent development of stenotic lesions later. The treatment for 
KD are reviewed and introduced as follows. 
4.1. Aspirin 
Aspirin has been used in the treatment of KD for many years, even before the usage of IVIG. 
Although aspirin has important anti-inflammatory (high dose) and anti-platelet (low dose) 
effects, it does not appear to reduce the frequency of CAL formation. During the acute phase 
of the illness, aspirin is administered in 4 doses of 80–100 mg/kg per day (30–50 mg/[kg·day] 
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in Japan)(50) with IVIG. High-dose aspirin and IVIG appear to possess additive anti-
inflammatory effects.  
Practices regarding the duration of high-dose aspirin administration vary across countries 
and centers, many of which reduce the aspirin dose when the patient is afebrile. When high-
dose aspirin is discontinued, low-dose aspirin (3–5 mg/[kg·day]) is administered until there 
is no evidence of CAL and inflammatory markers (including platelets, C-reactive protein 
[CRP], and erythrocyte sedimentation rate [ESR]) have returned to normal levels, which 
usually occurs 6–8 weeks after disease onset. For children who develop CAL, low-dose 
aspirin (or other anti-platelet agents) is continued indefinitely until the inflammatory mark-
ers return to the normal range and the echocardiogram does not display abnormalities. 
Hsieh et al.(50) reported that regardless of timing (before or after day 5 of the illness), single-
infusion, high-dose (2 g/kg) aspirin in the acute stage of KD had no effect on the response 
rate to IVIG therapy, duration of fever, or the incidence of CAL. This review reiterates the 
recommendation that exposing children to high-dose aspirin therapy in the acute phase of 
KD is unnecessary because available data show no appreciable benefit to IVIG therapy re-
sponse, CAL formation, or fever duration.  
Our recent study investigated 609 KD patients from 2 medical centers in Taiwan. The pa-
tients were divided into Group 1, receiving high-dose aspirin (N = 274), and Group 2, with-
out high-dose aspirin (N = 335). There were no significant differences between Groups 1 and 
2 in terms of gender (p = 0.51), IVIG resistance rate (34/274 vs. 26/335, p = 0.06), CAL for-
mation rate (57/274 vs. 74/335, p = 0.64), and total hospital stay (6.3 ± 0.2 vs. 6.7 ± 0.2 days, p 
= 0.13). There were also no significant differences between total white blood cell counts, 
hemoglobin levels, platelet counts, and CRP levels before (within 1 day) and after (within 3 
days) IVIG treatment of the 2 groups (p > 0.1). These results provide evidence that high-dose 
aspirin in the acute phase of KD does not affect the treatment results (CAL and IVIG re-
sistance rate) or inflammatory condition. High-dose aspirin treatment in the acute phase of 
KD appears unnecessary, and further randomized controlled trials are needed. 
However, Reye syndrome is a risk in children who receive salicylates while they are experi-
encing active infection with varicella or influenza and has been reported in patients receiv-
ing high-dose aspirin for a prolonged period after KD.(52) Taken together, it seems unneces-
sary to expose children to high-dose aspirin in acute KD, especially those with G6PD defi-
ciency. However, as reported in the literature, due to the anti-platelet effect, low-dose aspi-
rin has been prescribed for at least 6–8 weeks to prevent thrombocytosis in KD patients.(15) 
If patients are allergic or intolerant to a particular drug, clinicians must avoid using it and 
look for alternatives. Aspirin is used in most patients, often in conjunction with dipyridamo-
le. Dipyridamole has been widely used to treat patients with a coronary aneurysm resulting 
from KD.(43, 53) The relationship between aspirin therapy and hemolytic disorder in G6PD-
deficient patients is unclear. There are also no literature regarding usage of low-dose aspirin 
and the outcome of KD. G6PD deficiency, an X-linked disorder, is the most common enzy-
matic disorder of red blood cells in humans. The clinical expression of G6PD deficiency 
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encompasses a spectrum of hemolytic syndromes. While affected patients are usually 
asymptomatic, some have episodic anemia, while a few have chronic hemolysis. With the 
most prevalent G6PD variants (G6PD A- and G6PD Mediterranean), severe hemolysis is 
induced by the sudden destruction of older, more deficient erythrocytes after exposure to 
drugs with a high redox potential or to fava beans, selected infections, or metabolic abnor-
malities. The likelihood of developing hemolysis and the severity of disease are determined 
by the magnitude of the enzyme deficiency, which in turn is determined by the biochemical 
characteristics of the G6PD variant. The World Health Organization has classified the differ-
ent G6PD variants according to the magnitude of the enzyme deficiency and the severity of 
hemolysis.(54) Class I variants have severe enzyme deficiency (less than 10% of normal) and 
are associated with chronic hemolytic anemia. Class II variants also have severe enzyme 
deficiency, but are usually only intermittently associated with hemolysis. Class III variants 
have moderate enzyme deficiency (10–60% of normal), with intermittent hemolysis usually 
associated with infection or drugs. Class IV variants have no enzyme deficiency or hemoly-
sis. Class V variants have increased enzyme activity, and classes IV and V are of no clinical 
significance. The incidence of hemolysis development in a patient with G6PD deficiency 
after taking aspirin is dosage-related.(55) G6PD deficiency is commonly considered a contra-
indication to aspirin intake. However, just few studies(56) have suggested that aspirin can 
be safely administered in therapeutic doses to G6PD-deficient subjects without nonsphero-
cytic hemolytic anemia. Anti-platelet therapy is most commonly used to prevent thrombotic 
events for adults with atherosclerotic vascular disease, children with certain types of con-
genital heart disease, stroke, and KD.(57) Unfortunately, very little data on the efficacy and 
safety of anti-platelet therapy for pediatric patients, or even G6PD patients, are available. No 
prospective data exist to guide clinicians in selecting an optimal regimen. Therapeutic regi-
mens used in patients with KD depend on the severity of CAL and include anti-platelet 
therapy with aspirin, with or without dipyridamole or clopidogrel; anticoagulant therapy 
with warfarin or low-molecular-weight heparin; or a combination of anticoagulant and anti-
platelet therapy.(15)  
A few articles have reported G6PD-deficient patients with sustained KD.(58) However, the 
question of whether aspirin is suitable for KD patients with G6PD deficiency remains 
4.2. Intravenous immunoglobulin (IVIG or IVGG) responsiveness 
The efficacy of IVIG administered in the acute phase of KD for reducing the incidence of 
coronary artery abnormalities is well established.(59) The mechanism of IVIG action is still 
under investigation. IVIG appears to have a generalized anti-inflammatory effect. Possible 
mechanisms of action include modulation of cytokine production, neutralization of bacterial 
super-antigens or other etiologic agents, augmentation of regulatory T cell activity (TGF-
),(23, 26) suppression of antibody synthesis and inflammatory markers (CD40-CD40L, 
nitric oxide, and iNOS expression),(60-62) provision of anti-idiotypic antibodies, Fc-gamma 
receptor,(63) and balancing Th1/Th2 responses.(28-30)  
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KD patients should be treated with a single 12-hour infusion of 2 g/kg IVIG together with 
aspirin in the acute phase with fever or inflammation progression without fever.(3, 4, 15) 
This therapy should be administered within 10 days of illness onset, and if this is not 
possible, within 7 days of illness onset. Treatment of KD before day 5 of illness appears no 
more likely to prevent cardiac sequelae than treatment on days 5–9. However, it may be 
associated with an increased need for repeat IVIG treatment.(64, 65) In the presence of 4 of 5 
classic criteria for KD, US and Japanese experts agree that only 4 days of fever are necessary 
before initiating treatment with IVIG.(15, 66) 
The efficacy of treating patients using IVIG after 10 days of illness is unknown; therefore, 
early diagnosis and treatment is desired. IVIG should be administered to children 
presenting after day 10 of illness (i.e., children with delayed diagnosis or incomplete KD) if 
they have either persistent fever without explanation or aneurysms and ongoing systemic 
inflammation, as manifested by elevated ESR or CRP.(4, 67-69) Burns et al. also suggested 
that any child with KD who has evidence of persisting inflammation, including fever or 
high concentrations of inflammatory markers with or without coronary artery 
abnormalities, should be treated even if the diagnosis is made after 10 days of illness.(4) 
4.3. IVIG resistance (or IVIG unresponsiveness, initial IVIG treatment failure) 
The incidence of IVIG resistance varies from 9.4% to 23% between centers (but it can be as 
high as 38%, as reported in one US cohort).(70) Recent studies have identified demographic 
and laboratory characteristics as predictors of IVIG resistance, including age, illness day, 
platelet count, ESR, hemoglobin concentration, CRP, eosinophils, lactate dehydrogenase, 
albumin, and ALT.(5, 29, 71-73) As IVIG-resistant patients are at a higher risk for CAL 
formation, it is important to identify those who may benefit from more aggressive therapy. 
As shown in Figure 1 (modified from Newburger et al.(15)), there are no definite treatment 
principles available for the management of KD patients with initial IVIG resistance or 
unresponsiveness to other adjuvant therapies. A second dose of IVIG (1 or 2 g/kg),(15, 74) 
methylprednisolone (MP) pulse therapy,(75) tumor necrosis factor (TNF)- blockade,(76) 
cytotoxic agents (cyclophosphamide, cyclosporine A [CyA], or MTX(77)), plasmapheresis,(78) 
and plasma exchange(79) have been reported to benefit KD patients with initial IVIG 
treatment failure. These other treatment modalities will be discussed. 
4.4. Methylprednisolone pulse therapy 
At present, the usefulness of steroids in the initial treatment of KD is not well 
established.(15) Newburger et al. reported that, compared to conventional IVIG therapy for 
routine primary treatment of KD in children, a single-pulse dose of intravenous MP (IVMP) 
does not improve treatment outcome.(22) However, IVMP therapy appears to benefit IVIG-
resistant KD patients.(80) Miura et al. revealed the effectiveness of IVMP therapy for KD 
patients that were previously unresponsive to initial IVIG treatment. IVMP suppresses 
cytokine levels faster, and subsequently, the outcomes are similar to those of IVIG-
responsive patients who receive a second dose of IVIG.(81) Furukawa et al. reported similar 
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findings.(82) IVMP appears to have the same effect on IVIG-resistant KD patients compared 
to an additional IVIG treatment.(83) The cost-benefit differences between IVMP and 
additional IVIG should be carefully considered, taking into account different medical 
conditions or health insurance policies among countries. The first dose of IVIG is well 
established, while IVMP or additional IVIG for IVIG-resistant KD patients requires further 
investigation. Ogata et al.(83) reported that IVMP was useful for reducing fever duration 
and medical costs for KD patients with initial IVIG resistance. IVMP (N = 13) and additional 
IVIG treatment (N = 14) were not significantly different in terms of preventing the 
development of coronary artery aneurysm. IVMP (30 mg/kg MP per day for 3 days) or a 
second dose of IVIG (2 g/kg) was prescribed to KD patients with fever and marked 
inflammation (i.e., non-exudative conjunctival injection, strawberry tongue, fissured lips, 
and erythematous change at the BCG inoculation site) 48 hours after initial IVIG 
treatment.(22, 82-84)  
The safety of IVMP therapy in patients with KD is uncertain. Miura et al.(85) reported that 
IVMP (N = 11) incurred a higher incidence of sinus bradycardia and hyperglycemia when 
compared with the additional IVIG group (N = 11). Hypertension between IVMP and IVIG 
groups did not differ significantly. All of the adverse effects were transient. There were no 
convulsions, gastrointestinal symptoms, infections, malignant arrhythmias, or sudden death 
in any subject.(85) Taken together, IVMP is safe for KD patients as additional or adjuvant 
therapy of initial IVIG treatment.(22, 86, 87) After additional IVIG therapy, IVMP is 
considered for KD patients with persistently poor responses to the second IVIG 
treatment.(74, 88) Kobayashi et al.(89) reported that the addition of prednisolone (2 
mg/[kg·day] administered over 15 days) to the standard regimen of IVIG improves coronary 
artery outcomes in patients with severe KD in Japan.  
4.5. Tumor necrosis factor- blockade 
TNF- levels are elevated in children with KD,(90) and the TNF- (–308) genetic 
polymorphism is associated with KD susceptibility, suggesting a role for TNF- receptor 
blocking in the treatment of KD, especially for those patients/cases refractory to IVIG. The 
early administration of TNF- receptor antagonists in KD may provide effective adjunctive 
therapy. Infliximab, which binds the pro-inflammatory cytokine TNF-, has been evaluated 
in several studies and shown to have a significant effect in KD patients with IVIG 
resistance.(91-93) Recently, etanercept, a more suitable TNF- receptor blocker for children 
with refractory juvenile idiopathic arthritis,(94, 95) was reported to benefit the treatment of 
IVIG-resistant KD as an adjuvant therapy to initial IVIG.(96, 97) A TNF- receptor blocker 
may be administered after initial IVIG treatment failure or after a second dose of IVIG 
therapy. 
4.6. Statins 
Chronic vascular inflammation and endothelial dysfunction persists in KD patients with 
CAL, even long after the acute stage.(98, 99) There is currently no specific treatment for 
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ongoing vascular inflammation and endothelial dysfunction. Low-dose aspirin can be 
prescribed until CAL normalizes, but it does not have an effect on inflammation or 
endothelial dysfunction. Lipid abnormalities in the acute phase of KD, with decreased 
triglycerides and high-density lipoprotein cholesterol (HDL-C) levels have been reported in 
previous studies.(100, 101)  
Statins, hydroxymethylglutaryl coenzyme A reductase inhibitors, have been shown to re-
duce cholesterol levels as well as improve surrogate markers of atherosclerosis and cardio-
vascular disease.(102) Huang et al.(103) reported that short-term (3 months) statin treatment 
(simvastatin, 10 mg/day as a single dose at bedtime) in KD patients complicated with CAL 
(N = 11) can significantly reduce total cholesterol and low-density lipoprotein cholesterol 
levels and increase HDL-C levels. Chronic vascular inflammation is also significantly im-
proved, as is endothelial dysfunction, with no adverse effects. However, long-term and 
randomized control trials are needed before further conclusions can be drawn.  
Recently, Blankier et al.(104) also reported that atorvastatin is able to inhibit critical steps (T 
cell activation and proliferation, production of the pro-inflammatory cytokine TNF-, and 
upregulation of matrix metalloproteinase-9 and an elastolytic protease) known to be im-
portant in the development of coronary aneurysms in an animal model of KD (murine mod-
el with injection of Lactobacillus casei cell wall extract), suggesting that statins may have 
therapeutic benefits in KD patients. Taken together, statins may be beneficial as an adjuvant 
therapy in KD patients with CAL. However, the association between dyslipidemia and 
atherosclerosis in KD patients is not certain.  
4.7. Other treatments 
Acute KD can lead to the development of large coronary artery aneurysms that may persist 
for years. Abciximab, a platelet glycoprotein IIb/IIIa receptor inhibitor, is associated with 
resolution of thrombi and vascular remodeling in adults with acute coronary syndromes. 
Williams et al.(105) reported that KD patients who were treated with abciximab demonstrat-
ed greater regression in aneurysm diameter at early follow-up than patients who received 
standard therapy alone. McCandless et al.(106) also reported that abciximab treatment might 
be associated with vascular remodeling in patients with aneurysms. Abciximab appears to 
benefit KD patients, especially those who develop aneurysms.  
There are still no well-defined treatments for refractory KD. Suzuki et al.(107) reported that 
CyA treatment is considered safe and well tolerated and may serve as a promising option 
for patients with refractory KD. Hyperkalemia developed in 9 of 28 (32%) patients 3–7 days 
after commencing CyA treatment. Adverse effects such as arrhythmias should be monitored 
with CyA. Kuijpers et al.(108) described a case of mortality, and a review of the literature 
showed that immunosuppressive medication such as CyA may not influence coronary in-
flammation and proliferation. Further trials are needed to clarify the optimal dose, safety, 
and timing of CyA treatment.  
Current Basic and Pathological Approaches to  
the Function of Muscle Cells and Tissues – From Molecules to Humans 
 
220 
Specific changes in inflammatory markers (such as white blood cell count, neutrophil count, 
CRP, IL-6, soluble IL-2 receptor [sIL-2R](109), Th17/regulatory T-cell imbalance(110), and IL-
1 pathway(111)) have been reported to disrupt immunological functions and result in KD 
with IVIG resistance and CAL formation. This indicates the possible treatment role of 
plasma exchange (PE) for KD with IVIG resistance. Mori et al.(79) studied 46 children who 
had not responded to the second IVIG treatment and subsequently received PE, and 
compared them with 59 children that received a third dose of IVIG therapy. No 
complications occurred with PE therapy. CAL developed in 8 of the 46 children (17.3%) who 
received PE and in 24 of the 59 (40.7%) who received a third course of IVIG (p < 0.001). PE is 
considered safe and effective in the prevention of CAL in KD that is refractory to IVIG 
therapy. PE can be performed at an early stage, as soon as fractional increases in 
inflammatory markers are found after the first or second dosage of IVIG therapy.(79)  
5. Genetic association study in Kawasaki disease 
The higher incidence of KD in Asia, in conjunction with a higher incidence of the disease in 
Asian descendants compared with other ethnic populations in the United States and Eu-
rope, suggests that genetic predisposition might play an important role in the susceptibility 
to this disease.(3, 4, 9, 15) There is also evidence that the incidence of KD is higher among 
siblings than in the general population.(112) A growing number of research reports provide 
evidence that genetic polymorphisms contribute to the susceptibility to KD. For example, 
single-nucleotide polymorphisms (SNPs) in the monocyte chemoattractant protein 1 (MCP-
1),(113) IL-10,(114-116) CD40L,(117) CD40,(62) IL-4,(32) CASP3,(24) IL-18,(118) IL-1B,(119) 
HLA-E,(120) C-C chemokine receptor 5 (CCR5),(121-124) and ITPKC(20, 125, 126) and TGF- 
receptors(23) have been reported to be associated with the development of KD. Although 
genetic association studies have been widely performed in KD, several studies have pro-
duced inconsistent results. Some genes were proposed in one population; however, the 
findings could not be replicated in another population. In addition, the genes that are re-
sponsible for KD susceptibility may not be involved in CAL formation. Thus, studies ad-
dressing this question are plagued with inconsistencies. Three possibilities may explain 
these inconsistencies. First, some studies were performed in a small sample size that may 
not have been able to provide sufficient power to detect minor genetic effects. Second, it is 
becoming clear that there are different genetic backgrounds within populations that, due to 
variations in allele frequencies or heterogeneity of the phenotypes, may also influence the 
results. Third, the incidence of KD in Asia is much higher than that in other regions. Thus, 
the environmental factors or infectious agents between countries should also be considered 
carefully. 
6. Genetic polymorphisms of the ITPKC signaling pathway in Kawasaki 
disease 
A major advancement in the genetic study of KD was made by the discovery of ITPKC in the 
RIKEN SNP center Japan. In 2008, Onouchi and colleagues first identified a functional pol-
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ymorphism of ITPKC (rs28493229) that significantly associated with the susceptibility of KD 
and CAL in both Japanese and US children.(125) By using cell-based functional studies, 
Onouchi et al. further provided evidence to indicate that the risk C allele of ITPKC can re-
duce the splicing efficiency of the ITPKC mRNA that, in turn, contributes to the hyperactiva-
tion of Ca2+-dependent NFAT pathways in T cells. Thus, in the model of Onouchi et al., IT-
PKC is a negative regulator of T cells, and it may function as a calcium channel modulator 
that is involved in controlling immune systems. Interestingly, replication studies in the 
Taiwanese populations are strikingly controversial. The first replication study was by Chi et 
al. A total of 385 KD patients and 1158 normal subjects were genotyped.(127) However, no 
significant association was observed. Lin et al. took similar approaches in another independ-
ent medical center in Taipei. Their results indicated that the C allele of rs28493229 is associ-
ated with KD susceptibility.(128) Recently, data by meta-analysis support the correlation 
between rs28493229 of ITPKC and susceptibility of KD in the Taiwanese population.(23) Due 
to the increase in genetic diversity between cities in the south or north of Taiwan, we attrib-
ute the controversial results in the Taiwanese population to population migration. 
 
Figure 10. Model depicting the cellular pathways of ITPKC/calcium signaling in T cells. 
In the non-excitable cells such as T and B cells, calcium entry is mainly through store-
operated calcium channels (SOC). The activation of SOC can be controlled by the expres-
sion level of IP3, which is the substrate of ITPKC protein. As ITPKC is involved in the 
Ca2+-dependent NFAT signaling in T cells, genetic association studies between calcium 
pathways and susceptibility of KD were performed. The calcium-dependent downstream 
gene CASP3 is a good example. Onouchi et al. reported that a G-to-A substitution in the 
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5′-untranslated region of CASP3 (rs72689236) is associated with susceptibility to KD in 
Japanese and in Americans of European descent.(129) In the sample year, CASP3 
(rs72689236) was replicated in the KD children in the Taiwanese population.(24) Kuo et al. 
confirmed that the A allele of rs72689236 is very likely a risk allele in the development of 
aneurysms in patients with KD. Another 2 important molecules in the SOC are ORAI1 
(also known as CRACM1) and STIM1. Feske et al. identified ORAI1 in 2006. Modified 
linkage analysis completed on data generated by SNP arrays and RNA interference 
screening led to an important finding. A single missense mutation in ORAI1 was found in 
patients with severe combined immune deficiency syndrome. In 2011, genetic polymor-
phisms of ORAI1 were reported to associate with the risk and recurrence of calcium neph-
rolithiasis(130) and HLA-B27-positive AS(131). In the KD study, no significant association 
between OARI1 genotypes ORAI1 and KD clinical parameters (such as CAL formation or 
IVIG treatment responses) was found. However, a novel genetic polymorphism in the 
STIM1 gene was detected that associated with CAL formation in KD patients (data not 
shown). As STIM1 is a key initiator of SOC, DNA sequencing for the STIM1 gene family in 
a larger population may be helpful to identify novel polymorphisms. Future studies are 
needed to address the mechanism by which calcium signaling contributes to the devel-
opment of KD. (Figure 10)  
7. Genetic polymorphisms of the TGF- signaling pathway in Kawasaki 
disease 
TGF- is an important molecule that is involved in the regulation of cytokine expression and 
immune response. It has been shown that TGF--mediated signaling pathways are mainly 
via transcription factors, Smads, which include at least 3 common proteins: Smad2, Smad3, 
and Smad4. The binding of TGF- to its receptor results in the phosphorylation of Smad2 or 
Smad3, which heterodimerizes with Smad4. The formation of the Smad complex further 
translocates to the nulclus to regulate activation of the target genes. In the cardiovascular 
system, which is an important target of KD, TGF- signaling is involved in the pathogenesis 
of multiple cardiovascular diseases via aberrant vascular remodeling. Low expression levels 
of endogenous TGF- activity in the blood may contribute to the development of atheroscle-
rotic cardiovascular disease. In 2011, a large genetic study revealed a significant association 
between the polymorphisms in TGF- pathways and KD susceptibility or CAL formation in 
the European and US populations. In this study, Shimizu et al.(23) were the first to identify 
16 SNPs in 6 genes (TGFB2, TGFBR2, SMAD1, ENG, ACVRL1, and SMAD3) associated with 
the susceptibility to KD. The significance of genetic variation in 3 genes (SMAD3, TGFB2, 
and TGFBR2) could be replicated in the multiethnic TDT analysis from the independent 
United States/United Kingdom/Australia subjects. 
Kuo et al.(26) performed a replication study of 12 polymorphisms in 950 Taiwanese children. 
It was confirmed that genetic polymorphisms of SMAD as well as TGFB2 contribute to the 
susceptibility of KD. These observations, in combination with those of the recent study, 
support the importance of TGF- pathways for the susceptibility or severity of KD. 
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8. Genome-wide association study (GWAS) in Kawasaki disease 
In 2009, Burgner et al. were the first to perform a genome-wide association study (GWAS) on 
119 Caucasian KD cases and 135 matched controls. Forty SNPs and 6 haplotypes were con-
firmed in an independent cohort of KD families.(132) This insightful work led to the identifica-
tion of an SNP within the N-acetylated alpha-linked acidic dipeptidase-like 2 gene 
(NAALADL2; rs17531088), which was significantly associated with the susceptibility to KD. 
Although the function of NAALADL2 remains unclear, mutations in the gene may be involved 
in the development of Cornelia de Lange syndrome. In 2010, Kim et al. conducted another 
GWAS in a Korean population.(133) In total, 786 subjects (186 KD patients and 600 controls) 
were recruited. A locus in the 1p31 region was identified as a susceptibility locus for KD. Fur-
thermore, the PELI1 gene locus in the 2p13.3 region was confirmed to associate with the devel-
opment of CAL in KD patients. In 2012, two independent research groups by Lee et al.(62) and 
Onouchi et al.(134) published GWAS data from Taiwanese and Japanese populations, respec-
tively. The results suggested that BLK (encoding B-lymphoid tyrosine kinase) and CD40 are 
novel susceptibility genes for KD. Consistent with this findings, Kuo et al. conducted a case–
control genetic association study and identified another polymorphism in the CD40 gene that 
associated with susceptibility to KD. Hence, the results from independent groups support a 
significant role of immune-related genes such as CD40 for KD and CAL formation.(135)  
9. Conclusion 
Several major advances have been made in understanding the genetic effects of the suscep-
tibility and clinical status of KD over the past decade. Very recently, genome-wide associa-
tion led 2 groups (Lee et al. and Onouchi et al.) to identify the same novel susceptibility loci 
as being important for KD in the Asian population. Although the exact functional role of 
these genes in KD is still unclear, at present, these loci could provide a new direction for 
future studies. We can expect to see more insightful research beginning to elucidate the 
genes responsible for KD susceptibility. 
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